Table 1.
Author | Year | Ethnicity | Number of patient | Trial design | Cancer type | Cutoff value of positive Gal-9 | Localization of Gal-9 | Follow-up (months) Medium (range) | Outcomes | Model | Method | Specimen | NOS score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Irie | 2005 | Eastern Asian | 84 | PC | Breast cancer | H-score > 80 | C | 188 | DFS | Uni | IHC | PEB | 8 |
Zhang | 2012 | Eastern Asian | 200 | RC | HCC | Score > 2, (0–7) | C | ≥60 | OS | Multi | IHC | PEB | 7 |
Gu | 2013 | Eastern Asian | 147 | PC | HCC | NA | C, M, N | 24.4(9–43) | OS, DFS | Multi | IHC | NA | 8 |
Jiang | 2013 | Eastern Asian | 183 | PC | Gastric cancer | H-score > 200 | C | 40(3–135) | OS | Uni | IHC | PEB | 8 |
Kong | 2014 | Eastern Asian | 197 | PC | HCC | H-score > 100 | C | 21(12–56) | OS | Uni | IHC | PEB | 8 |
Schulkens | 2014 | Caucasian | 87 | RC | NSCLC | ≥median | NA | ≥60 | OS, DFS | Uni | qRT-PCR | Frozen tissue | 5 |
Fu | 2015 | Eastern Asian | 196 | RC | Urinary tumors | H-score ≥ median | NA | 106(12–120) | OS, RFS | Multi | IHC | PEB | 7 |
Grosset | 2016 | Caucasian | 98 | RC | Breast cancer | NA | C, N | 60 | DFS | Uni | IHC | PEB | 5 |
Ohue | 2016 | Eastern Asian | 120 | PC | NSCLC | Score = =3,4,6 | C, M | NA | OS | Multi | IHC | PEB | 8 |
Wang | 2016 | Eastern Asian | 90 | PC | Colon cancer | Score = =2,3,4 | C | 96 | OS | Multi | IHC | PEB | 8 |
Choi | 2017 | Eastern Asian | 619 | PC | Gastric cancer | ≥10% of cells | HA | 65.7(0–79) | OS | Multi | IHC | PEB | 8 |
Liu | 2017 | Eastern Asian | 202 | RC | Urinary tumors | H-score = 58–157 | C | 60.5 | OS, RFS | Multi | IHC | PEB | 7 |
Melief | 2017 | Caucasian | 73 | PC | Melanoma | >Median Z-cores | NA | Upto 120 | OS | Multi | IFS | PEB | 8 |
Sideras | 2017 | Caucasian | 94 | RC | HCC | Score = 1,2,3 (0–3) | C | NA | OS | Multi | IHC | PEB | 7 |
PC, prospective cohort; RC, retrospective cohort; HCC: hepatocellular carcinoma; NSCLC, non-small cell lung cancer; C, cytoplasm; M, cell membrane; N, nucleus; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; Multi, multivariate; Uni, univariate; IHC, immunohistochemistry; IFS, immunofluorescence staining; qRT-PCR, quantitative real-time polymerase chain reaction; PEB, paraffin embedded block; N.A., not available.